A Phase 1 clinical trial testing therapy candidate STRO-001 for lymphoma and myeloma has started treating its first patients, announced Sutro Biopharma, the therapy’s maker. The open-label, multicenter trial (NCT03424603) will test the investigational treatment in patients who are intolerant or in whom all other available therapies have failed. Promising preclinical data has shown that STRO-001 could eliminate or significantly…
